Project Grant HT94252510851
Award Date 10/1/25
Completion Date 9/30/28
Dollars Obligated $1.4M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,348,314.00 to The University of Texas MD Anderson Cancer Center to conduct research on building T-cell products for neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors (NF1-associated MPNST) through antigen discovery and epigenome targeting. The research aims to transform healthcare for military service members, veterans, and the...
- This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $489,767 to The University of Texas M.D. Anderson Cancer Center in Houston, TX to support research on building T-cell products for the treatment of NF1-associated malignant peripheral nerve sheath tumors (MPNST). The project aims to advance the understanding of MPNST through antigen discovery and epigenome targeting, with the goal of developing improved...
- The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $931,113 project grant to The University of Texas MD Anderson Cancer Center, with a performance period from November 1, 2024 to October 31, 2027. The grant supports research targeting RNA surveillance machinery in neurofibromatosis type 1 (NF1)-mutant malignant peripheral nerve sheath tumors (MPNSTs). As a leading academic cancer research institution, MD Anderson has extensive expertise...
- The University of Texas MD Anderson Cancer Center received a $1,041,605 Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to conduct research titled "INTERROGATING TUMOR-IMMUNE-NEURON CROSS TALK AT SINGLE-CELL RESOLUTION IN A PANEL OF NOVEL SOMATIC TRANSGENIC NF1 TUMOR MODELS". This 3-year award, starting on September 1, 2023, will support basic and translational cancer research focused on understanding the interactions...
- This $414,472 federal Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research at The University of Texas M.D. Anderson Cancer Center to investigate neuronal mimicry in the treatment of SMARCB1-deficient renal medullary carcinoma. The 3-year award, effective from September 1, 2025 through August 31, 2028, will fund advanced biomedical research aimed at transforming healthcare for military service members,...
- This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $5,471,258.00 to The University of Texas MD Anderson Cancer Center in Houston, Texas to conduct advanced biomedical research targeting ganglioside GD2 with the goal of overcoming chemotherapy resistance in triple-negative breast cancer. The research aims to transform healthcare for military service members, veterans, and the broader public by...
- This $505,071 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports research by the University of Texas MD Anderson Cancer Center to discover novel antigens in triple-negative breast cancer for the development of innovative T-cell therapies. The award period runs from February 15, 2025 to February 14, 2028, with the ultimate goal of transforming healthcare for military service members, veterans, and the broader...
- The Defense Health Agency awarded a $819,080 Project Grant to The University of Texas M.D. Anderson Cancer Center to evaluate how maternal dietary exposure affects neurodevelopment and cognition in neurofibromatosis type 1 (NF1) under the Military Medical Research and Development program (CFDA 12.420). The University of Texas M.D. Anderson Cancer Center will conduct research into medical solutions for the battlefield and innovative healthcare for service members and the public by investigating...
- This $1,626,438 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports advanced biomedical research by the University of Texas MD Anderson Cancer Center to address critical health challenges for military service members, veterans, and the broader public. The funding will enable the cancer center to conduct diverse medical research investigations spanning basic, applied, and translational domains, with a focus on...
- The University of Texas MD Anderson Cancer Center received a $647,990 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). This three-year grant, effective June 1, 2024, supports research to investigate cell plasticity and epigenetic reprogramming mechanisms underlying the transition of well-differentiated to de-differentiated liposarcoma. The funding will enable basic research, translational studies, and potentially future...